REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Habrantus-Pharma Bt. (Hungary)

Main Activities: Pharmacies and Drug Stores
Full name: HABRANTUS-PHARMA Gyogyszeripari Termekeket Termelo, Szolgaltato, Kereskedelmi Bt. Profile Updated: October 31, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Hungarian Download a sample report

Habrantus-Pharma Bt. is an enterprise located in Hungary, with the main office in Budapest. The company operates in the Pharmacies and Drug Stores industry. It was incorporated on May 22, 1993. 11 (2024) employees currently work for Habrantus-Pharma Bt.. In 2023, the company reported a net sales revenue increase of 18.17%. Its’ total assets recorded a growth of 17.89%. Habrantus-Pharma Bt.’s net profit margin decreased by 0.02% in 2023.

Headquarters
Jokai u. 2-4.
Budapest; Budapest; Postal Code: 1165

Contact Details: Purchase the Habrantus-Pharma Bt. report to view the information.

Basic Information
Total Employees:
Purchase the Habrantus-Pharma Bt. report to view the information.
Outstanding Shares:
Purchase the Habrantus-Pharma Bt. report to view the information.
Registered Capital:
Purchase the Habrantus-Pharma Bt. report to view the information.
Financial Auditors:
Purchase the Habrantus-Pharma Bt. report to view the information.
Incorporation Date:
May 22, 1993
Key Executives
Purchase this report to view the information.
Managing Director
Ownership Details
Purchase this report to view the information.
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after Habrantus-Pharma Bt. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency HUF. Absolute financial data is included in the purchased report.
Net sales revenue
18.17%▲
Total operating revenue
18.1%▲
Operating profit (EBIT)
13.21%▲
EBITDA
13.13%▲
Net Profit (Loss) for the Period
17.97%▲
Total assets
17.89%▲
Total equity
17.82%▲
Operating Profit Margin (ROS)
-0.36%▼
Net Profit Margin
-0.02%▼
Return on Equity (ROE)
0.12%▲
Quick Ratio
0.03%▲
Cash Ratio
0.01%▲

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo